Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease?

被引:76
|
作者
Baron, Frederic [1 ,2 ,3 ]
Storb, Rainer [4 ,5 ]
机构
[1] Univ Liege, Div Hematol, Dept Med, B-4000 Liege, Belgium
[2] CHU Liege, Liege, Belgium
[3] Univ Liege, GIGA I3, B-4000 Liege, Belgium
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Washington, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Mesenchymal stromal cells; MSC; Graft-versus-host disease; GVHD; Allogeneic hematopoietic cell transplantation; HUMAN-BONE-MARROW; MIXED HEMATOPOIETIC CHIMERISM; PROLIFERATION IN-VITRO; TOTAL-BODY IRRADIATION; IDENTICAL LITTERMATE DOGS; COLONY-STIMULATING FACTOR; SUPPRESS T-LYMPHOCYTE; 20-YEAR FOLLOW-UP; EX-VIVO CULTURE; STEM-CELLS;
D O I
10.1016/j.bbmt.2011.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mesenchymal stromal cells (MSCs) represent a heterogeneous subset of multipotent cells that can be isolated from several tissues including bone marrow and fat. MSCs exhibit immunomodulatory and anti-inflammatory properties that prompted their clinical use as prevention and/or treatment for severe graft-versus-host disease (GVHD). Although a number of phase I-II studies have suggested that MSC infusion was safe and might be effective for preventing or treating acute GVHD, definitive proof of their efficacy remains lacking thus far. Multicenter randomized studies are ongoing to more precisely assess the impact of MSC infusion on GVHD prevention/treatment, whereas further research is performed in vitro and in animal models with the aims of determining the best way to expand MSCs ex vivo as well as the most efficient dose and schedule of MSCs 'administration. After introducing GVHD, MSC biology, and results of MSC infusion in animal models of allogeneic hematopoietic cell transplantation, this article reviews the results of the first clinical trials investigating the use of MSC infusion as prevention or treatment of GVHD. Biol Blood Marrow Transplant 18: 822-840 (2012) (C) 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:822 / 840
页数:19
相关论文
共 50 条
  • [31] Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence
    Rizk, Mina
    Monaghan, Madeline
    Shorr, Risa
    Kekre, Natasha
    Bredeson, Christopher N.
    Allan, David S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1416 - 1423
  • [32] Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases
    Lim, Joo Han
    Lee, Moon Hee
    Yi, Hyeon Gyu
    Kim, Chul Soo
    Kim, Jun Hyung
    Song, Sun U.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 204 - 207
  • [33] IMMUNOMONITORING OF PATIENTS TREATED WITH MESENCHYMAL STROMAL CELLS FOR STEROID-REFRACTORY SEVERE GRAFT-VERSUS-HOST DISEASE
    Keto, J.
    Kaartinen, T.
    Salmenniemi, U.
    Partanen, J.
    Hanninen, A.
    Lahteenmaki, K.
    Korhonen, M.
    Itala-Remes, M.
    Nystedt, J.
    CYTOTHERAPY, 2017, 19 (05) : S127 - S127
  • [34] Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases
    Joo Han Lim
    Moon Hee Lee
    Hyeon Gyu Yi
    Chul Soo Kim
    Jun Hyung Kim
    Sun U. Song
    International Journal of Hematology, 2010, 92 : 204 - 207
  • [35] Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study
    Kuzmina, Larisa A.
    Petinati, Natalia A.
    Parovichnikova, Elena N.
    Lubimova, Lidia S.
    Gribanova, Elena O.
    Gaponova, Tatjana V.
    Shipounova, Irina N.
    Zhironkina, Oxana A.
    Bigildeev, Alexey E.
    Svinareva, Daria A.
    Drize, Nina J.
    Savchenko, Valery G.
    STEM CELLS INTERNATIONAL, 2012, 2012
  • [36] Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model
    Thielen, Frederick W.
    Blommestein, Hedwig M.
    Oosten, Liesbeth E. M.
    Calkoen, Friso G.
    Lankester, Arjan C.
    Zwaginga, Jaap J.
    Le Blanc, Katarina
    Redondo, Alba
    Sanchez-Guijo, Fermin
    Algeri, Mattia
    Locatelli, Franco
    Fibbe, Wim E.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (05) : 676 - 683
  • [37] Modelling the effects of acute graft-versus-host disease on recipient bone-marrow mesenchymal stromal cells
    Fasslrinner, F.
    Wobus, M.
    Duryagina, R.
    Mueller, K.
    Schmitz, M.
    Bornhaeuser, M.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S156 - S157
  • [38] Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival
    Galleu, Antonio
    Milojkovic, Dragana
    Deplano, Simona
    Szydlo, Richard
    Loaiza, Sandra
    Wynn, Robert
    Marks, David I.
    Richardson, Deborah
    Orchard, Kim
    Kanfer, Edward
    Tholouli, Eleni
    Saif, Muhammad
    Sivaprakasam, Ponni
    Lawson, Sarah
    Bloor, Adrian
    Pagliuca, Antonio
    Potter, Victoria
    Mehra, Varun
    Snowden, John A.
    Vora, Ajay
    Kishore, Bhuvan
    Hunter, Hannah
    Apperley, Jane F.
    Dazzi, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) : 89 - 92
  • [39] Multipotent Mesenchymal Stromal Cells as Graft-Versus-Host Disease Prophylaxis: a Prospective Randomised Clinical Trial.
    Petinaty, Natalia A.
    Shipounova, Irina N.
    Kuzmina, Larisa A.
    Lubimova, Lidya S.
    Parovichnikova, Elena N.
    Gribanova, Elena O.
    Petrov, Michail M.
    Drize, Nina I.
    Savchenko, Valeri G.
    BLOOD, 2010, 116 (21) : 538 - 538
  • [40] Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease—friends or foes?
    A Balan
    G Lucchini
    S Schmidt
    A Schneider
    L Tramsen
    S Kuçi
    R Meisel
    P Bader
    T Lehrnbecher
    Leukemia, 2014, 28 : 1941 - 1948